The stock of Quest Diagnostics, Inc. (DGX) has seen a 5.44% increase in the past week, with a 2.27% gain in the past month, and a 9.42% flourish in the past quarter. The volatility ratio for the week is 2.31%, and the volatility levels for the past 30 days are at 1.82% for DGX. The simple moving average for the last 20 days is 4.26% for DGX stock, with a simple moving average of 12.72% for the last 200 days.
Is It Worth Investing in Quest Diagnostics, Inc. (NYSE: DGX) Right Now?
Quest Diagnostics, Inc. (NYSE: DGX) has a price-to-earnings ratio of 21.14x that is above its average ratio. Additionally, the 36-month beta value for DGX is 0.89. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 14 rating it as “hold,” and 1 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for DGX is 110.77M and currently, short sellers hold a 1.78% ratio of that float. The average trading volume of DGX on October 23, 2024 was 781.41K shares.
DGX) stock’s latest price update
Quest Diagnostics, Inc. (NYSE: DGX)’s stock price has plunge by 6.85relation to previous closing price of 147.37. Nevertheless, the company has seen a 5.44% surge in its stock price over the last five trading sessions. youtube.com reported 2024-10-22 that One of the biggest earnings movers from Tuesday: Quest Diagnostics (DGX). The lab & testing company beat on the top-and-bottom line in its 3Q report, as shares surged to multi-month highs.
Analysts’ Opinion of DGX
Many brokerage firms have already submitted their reports for DGX stocks, with Evercore ISI repeating the rating for DGX by listing it as a “In-line.” The predicted price for DGX in the upcoming period, according to Evercore ISI is $165 based on the research report published on August 28, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see DGX reach a price target of $165, previously predicting the price at $145. The rating they have provided for DGX stocks is “Buy” according to the report published on July 10th, 2024.
Leerink Partners gave a rating of “Market Perform” to DGX, setting the target price at $135 in the report published on February 26th of the current year.
DGX Trading at 3.18% from the 50-Day Moving Average
After a stumble in the market that brought DGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.19% of loss for the given period.
Volatility was left at 1.82%, however, over the last 30 days, the volatility rate increased by 2.31%, as shares surge +2.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.69% upper at present.
During the last 5 trading sessions, DGX rose by +5.44%, which changed the moving average for the period of 200-days by +10.91% in comparison to the 20-day moving average, which settled at $151.03. In addition, Quest Diagnostics, Inc. saw 14.21% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DGX starting from PREVOZNIK MICHAEL E, who sale 32,551 shares at the price of $154.97 back on Aug 29 ’24. After this action, PREVOZNIK MICHAEL E now owns 38,478 shares of Quest Diagnostics, Inc., valued at $5,044,516 using the latest closing price.
KUPPUSAMY KARTHIK, the SVP, Clinical Solutions of Quest Diagnostics, Inc., sale 1,990 shares at $153.26 during a trade that took place back on Aug 28 ’24, which means that KUPPUSAMY KARTHIK is holding 11,459 shares at $304,990 based on the most recent closing price.
Stock Fundamentals for DGX
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.16 for the gross margin
The net margin for Quest Diagnostics, Inc. stands at 0.13. The total capital return value is set at 0.09. Equity return is now at value 12.66, with 5.67 for asset returns.
Based on Quest Diagnostics, Inc. (DGX), the company’s capital structure generated 0.51 points at debt to capital in total, while cash flow to debt ratio is standing at 0.2. The debt to equity ratio resting at 1.02. The interest coverage ratio of the stock is -13.5.
Currently, EBITDA for the company is 1.79 billion with net debt to EBITDA at 5.29. When we switch over and look at the enterprise to sales, we see a ratio of 2.49. The receivables turnover for the company is 6.93for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.25.
Conclusion
In conclusion, Quest Diagnostics, Inc. (DGX) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
